Barclays analyst Carter Gould raised the firm’s price target on Travere Therapeutics to $18 from $14 and keeps an Overweight rating on the shares. The forthcoming focal segmental glomerulosclerosis updates should provide a “steady set of catalysts de-risking regulatory path,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target lowered to $22 from $23 at Canaccord
- Travere Therapeutics price target lowered to $17 from $19 at Wedbush
- Travere selloff on trial pause an opportunity, says Citi
- Travere Therapeutics price target lowered to $18 from $19 at BofA
- Travere Therapeutics price target lowered to $23 from $25 at Guggenheim